Form 4: Bristol-Myers Squibb CFO Elkins Reports Equity Transactions

Bristol-Myers Squibb's EVP and Chief Financial Officer, David V. Elkins, reported the vesting of market share units and performance shares, along with new equity grants.

Summary

• David V. Elkins, EVP, Chief Financial Officer of Bristol-Myers Squibb Co (BMY), reported multiple equity transactions on March 10, 2026.
• Elkins acquired a total of 62,982 shares of common stock through the vesting of market share units (7,654 from a 2022 grant and 7,904 from a 2023 grant) and the distribution of performance shares (47,424 from a 2023-2025 award).
• He disposed of a total of 41,113 shares of common stock, including 16,114 shares withheld for tax payments at a price of $60.13 per share, and 24,999 shares due to downward adjustments based on performance factors.
• Following these transactions, Elkins' direct beneficial ownership of common stock is 189,248 shares.
• Elkins also holds an indirect beneficial ownership of 291.17 shares in the BMS Savings and Investment Program.
• New derivative security grants include 35,265 Market Share Units and 52,898 Performance Shares, both granted on March 10, 2026, and scheduled to cliff vest on March 10, 2029.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine executive compensation activities and continued alignment of the CFO's interests with long-term company performance. The new grants reinforce a commitment to future value creation.

Positives

• Vesting of previously granted market share units and performance shares indicates successful achievement of performance criteria and retention.
• New grants of 35,265 Market Share Units and 52,898 Performance Shares align the CFO's long-term incentives with shareholder value creation, vesting in 2029.

Negatives

• A total of 24,999 shares were disposed due to downward adjustments based on performance factors, indicating that some performance targets were not fully met.
• 16,114 shares were withheld for tax payments upon the vesting of awards, which is a common practice but reduces the net shares received by the executive.

Risks

• Future payouts from market share units and performance shares are subject to company performance and stock price fluctuations, as determined by payout factors and relative total shareholder return (rTSR) metrics.
• The value of equity compensation is directly tied to the market performance of Bristol-Myers Squibb's common stock.

Future Outlook

The new grants of market share units and performance shares, which cliff vest in March 2029, indicate a long-term incentive structure designed to align executive performance with the company's strategic goals and shareholder returns over the next three years.

Industry Context

StockSavvy.ai notes these transactions are typical for executive long-term incentive plans in the pharmaceutical industry, aligning executive interests with shareholder value over multi-year performance periods. The use of market share units and performance shares with payout factors tied to stock price and relative total shareholder return is a common practice to incentivize performance and retention among senior leadership.

Comparison to Industry Standards

• The structure of equity compensation, including Market Share Units (MSUs) and Performance Shares, is consistent with executive compensation practices at major pharmaceutical companies such as Pfizer, Merck, and Johnson & Johnson.
• Payout factors based on stock price performance and relative Total Shareholder Return (rTSR) are standard mechanisms used to link executive compensation directly to shareholder returns and competitive performance within the industry.
• The practice of withholding shares for tax obligations upon vesting is a routine and widely accepted method across publicly traded companies for managing executive compensation.

Stakeholder Impact

• Shareholders: The equity transactions, particularly the new grants, reinforce the alignment of the Chief Financial Officer's financial interests with the long-term performance and shareholder value of Bristol-Myers Squibb.

Next Steps

• Future vesting of 7,904 remaining market share units from the 2023 grant on March 10, 2027.
• Cliff vesting of 35,265 newly granted market share units on March 10, 2029.
• Cliff vesting of 52,898 newly granted performance shares on March 10, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the vesting of prior awards and new grants. It does not contain information that would fundamentally alter the investment thesis for Bristol-Myers Squibb, thus a 'hold' recommendation is appropriate as it reflects standard operational compensation practices rather than new strategic or financial performance insights.

Keywords

Bristol-Myers Squibb, BMY, SEC Form 4, Insider Transaction, Equity Compensation, Market Share Units, Performance Shares, David V. Elkins, CFO, Executive Compensation